25 XP   0   0   10

Kalvista Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Kalvista together

PenkeI guess you are interested in Kalvista Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kalvista Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kalvista Pharmaceuticals Inc

I send you an email if I find something interesting about Kalvista Pharmaceuticals Inc.

Quick analysis of Kalvista (30 sec.)










What can you expect buying and holding a share of Kalvista? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.10
Expected worth in 1 year
$4.19
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$2.09
Return On Investment
18.0%

For what price can you sell your share?

Current Price per Share
$11.65
Expected price per share
$9.89 - $16.88
How sure are you?
50%

1. Valuation of Kalvista (5 min.)




Live pricePrice per Share (EOD)

$11.65

Intrinsic Value Per Share

$-33.75 - $-17.44

Total Value Per Share

$-31.65 - $-15.34

2. Growth of Kalvista (5 min.)




Is Kalvista growing?

Current yearPrevious yearGrowGrow %
How rich?$88.5m$169.4m-$43.6m-34.7%

How much money is Kalvista making?

Current yearPrevious yearGrowGrow %
Making money-$30.5m-$21.4m-$9m-29.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Kalvista (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#399 / 1019

Most Revenue
#771 / 1019

Most Profit
#801 / 1019

Most Efficient
#212 / 1019

What can you expect buying and holding a share of Kalvista? (5 min.)

Welcome investor! Kalvista's management wants to use your money to grow the business. In return you get a share of Kalvista.

What can you expect buying and holding a share of Kalvista?

First you should know what it really means to hold a share of Kalvista. And how you can make/lose money.

Speculation

The Price per Share of Kalvista is $11.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kalvista.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kalvista, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.10. Based on the TTM, the Book Value Change Per Share is $0.52 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kalvista.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.69-5.9%-0.64-5.5%-0.28-2.4%-0.35-3.0%-0.23-2.0%
Usd Book Value Change Per Share-0.61-5.3%0.524.5%-1.23-10.6%-0.02-0.2%0.070.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.61-5.3%0.524.5%-1.23-10.6%-0.02-0.2%0.070.6%
Usd Price Per Share15.77-10.72-9.53-13.77-9.92-
Price to Earnings Ratio-5.73--4.15--1,013.37--213.32--118.02-
Price-to-Total Gains Ratio-25.72--14.38-2,935.25-553.29-290.07-
Price to Book Ratio7.51-3.98-523.39-109.24-57.50-
Price-to-Total Gains Ratio-25.72--14.38-2,935.25-553.29-290.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.65
Number of shares85
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.52-0.02
Usd Total Gains Per Share0.52-0.02
Gains per Quarter (85 shares)44.48-1.56
Gains per Year (85 shares)177.92-6.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101781680-6-16
203563460-12-22
305345240-19-28
407127020-25-34
508908800-31-40
60106810580-37-46
70124512360-44-52
80142314140-50-58
90160115920-56-64
100177917700-62-70

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.041.00.02.4%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%8.030.02.020.0%8.031.03.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.042.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%8.030.02.020.0%8.031.03.019.0%

Fundamentals of Kalvista

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 12:36:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kalvista Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kalvista earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-93.5%+93.5%
5Y-93.5%10Y-18,679.4%+18,585.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y-93.5%-436.8%+343.3%
10Y-18,679.4%-599.3%-18,080.1%
1.1.2. Return on Assets

Shows how efficient Kalvista is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • -25.5% Return on Assets means that Kalvista generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is -25.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.5%TTM-20.8%-4.7%
TTM-20.8%YOY-11.5%-9.3%
TTM-20.8%5Y-11.8%-9.0%
5Y-11.8%10Y-16.2%+4.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.5%-13.6%-11.9%
TTM-20.8%-12.9%-7.9%
YOY-11.5%-11.9%+0.4%
5Y-11.8%-14.2%+2.4%
10Y-16.2%-16.2%+0.0%
1.1.3. Return on Equity

Shows how efficient Kalvista is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • -32.8% Return on Equity means Kalvista generated $-0.33 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is -32.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.8%TTM-25.0%-7.8%
TTM-25.0%YOY-12.8%-12.2%
TTM-25.0%5Y-13.5%-11.4%
5Y-13.5%10Y-11.3%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.8%-17.0%-15.8%
TTM-25.0%-16.1%-8.9%
YOY-12.8%-15.4%+2.6%
5Y-13.5%-20.0%+6.5%
10Y-11.3%-21.1%+9.8%

1.2. Operating Efficiency of Kalvista Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kalvista is operating .

  • Measures how much profit Kalvista makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-123.5%+123.5%
5Y-123.5%10Y-16,246.3%+16,122.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y-123.5%-475.2%+351.7%
10Y-16,246.3%-624.7%-15,621.6%
1.2.2. Operating Ratio

Measures how efficient Kalvista is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.298-2.298
5Y2.29810Y249.791-247.492
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y2.2985.675-3.377
10Y249.7917.857+241.934

1.3. Liquidity of Kalvista Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kalvista is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.44 means the company has $5.44 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 5.442. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.689. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.442TTM8.689-3.246
TTM8.689YOY16.037-7.349
TTM8.6895Y13.748-5.059
5Y13.74810Y10.888+2.860
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4423.930+1.512
TTM8.6894.251+4.438
YOY16.0375.436+10.601
5Y13.7486.045+7.703
10Y10.8886.363+4.525
1.3.2. Quick Ratio

Measures if Kalvista is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • A Quick Ratio of 7.94 means the company can pay off $7.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 7.936. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.537. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.936TTM12.537-4.602
TTM12.537YOY24.442-11.905
TTM12.5375Y21.792-9.255
5Y21.79210Y14.902+6.890
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9363.629+4.307
TTM12.5374.065+8.472
YOY24.4425.397+19.045
5Y21.7925.993+15.799
10Y14.9026.277+8.625

1.4. Solvency of Kalvista Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kalvista assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kalvista to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Kalvista assets are financed with 22.3% credit (debt) and the remaining percentage (100% - 22.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 0.223. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.162. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.223TTM0.162+0.060
TTM0.162YOY0.100+0.063
TTM0.1625Y0.118+0.045
5Y0.11810Y0.919-0.801
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2230.332-0.109
TTM0.1620.334-0.172
YOY0.1000.268-0.168
5Y0.1180.366-0.248
10Y0.9190.390+0.529
1.4.2. Debt to Equity Ratio

Measures if Kalvista is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kalvista to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.7% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kalvista Pharmaceuticals Inc:

  • The MRQ is 0.287. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.197. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.197+0.090
TTM0.197YOY0.111+0.086
TTM0.1975Y0.136+0.061
5Y0.13610Y0.203-0.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2870.381-0.094
TTM0.1970.390-0.193
YOY0.1110.334-0.223
5Y0.1360.434-0.298
10Y0.2030.466-0.263

2. Market Valuation of Kalvista Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kalvista generates.

  • Above 15 is considered overpriced but always compare Kalvista to the Biotechnology industry mean.
  • A PE ratio of -5.73 means the investor is paying $-5.73 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kalvista Pharmaceuticals Inc:

  • The EOD is -4.233. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.730. Based on the earnings, the company is expensive. -2
  • The TTM is -4.149. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.233MRQ-5.730+1.497
MRQ-5.730TTM-4.149-1.581
TTM-4.149YOY-1,013.369+1,009.219
TTM-4.1495Y-213.325+209.176
5Y-213.32510Y-118.016-95.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.233-2.315-1.918
MRQ-5.730-2.560-3.170
TTM-4.149-2.664-1.485
YOY-1,013.369-4.122-1,009.247
5Y-213.325-6.258-207.067
10Y-118.016-6.108-111.908
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kalvista Pharmaceuticals Inc:

  • The EOD is -4.454. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.029. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.611. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.454MRQ-6.029+1.575
MRQ-6.029TTM-4.611-1.417
TTM-4.611YOY-1,889.662+1,885.051
TTM-4.6115Y-391.247+386.635
5Y-391.24710Y-200.165-191.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.454-3.067-1.387
MRQ-6.029-3.251-2.778
TTM-4.611-3.545-1.066
YOY-1,889.662-5.595-1,884.067
5Y-391.247-8.315-382.932
10Y-200.165-8.708-191.457
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kalvista is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.51 means the investor is paying $7.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kalvista Pharmaceuticals Inc:

  • The EOD is 5.548. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.511. Based on the equity, the company is overpriced. -1
  • The TTM is 3.983. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.548MRQ7.511-1.962
MRQ7.511TTM3.983+3.527
TTM3.983YOY523.392-519.409
TTM3.9835Y109.241-105.258
5Y109.24110Y57.499+51.742
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5481.905+3.643
MRQ7.5112.111+5.400
TTM3.9832.095+1.888
YOY523.3922.836+520.556
5Y109.2413.443+105.798
10Y57.4993.794+53.705
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kalvista Pharmaceuticals Inc.

3.1. Institutions holding Kalvista Pharmaceuticals Inc

Institutions are holding 93.686% of the shares of Kalvista Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30TANG CAPITAL MANAGEMENT LLC8.2754.6749344034578895229.7561
2023-12-31TCG Crossover Management, LLC8.16724.6129339549500
2023-09-30VR Adviser, LLC7.01542.9568291666700
2023-12-31Suvretta Capital Management, LLC6.45581.4865268400526315410.8703
2023-12-31BlackRock Inc5.39270.0007224202559727836.3143
2023-12-31Saturn V Capital Management LLC4.34778.47571807563-2683-0.1482
2023-12-31Vanguard Group Inc4.28480.00051781419489302.8243
2023-12-31Boxer Capital LLC3.96871.0074165000000
2023-12-31Jefferies Financial Group Inc2.59770.08631080000500004.8544
2023-12-31Driehaus Capital Management LLC2.4740.15181028568-6055-0.5852
2023-09-30Citadel Advisors Llc2.23330.0019928502818969.6734
2023-12-31Vivo Capital, LLC2.05890.858685600800
2023-12-31Dimensional Fund Advisors, Inc.1.72450.002671696413405922.9984
2023-12-31Adage Capital Partners Gp LLC1.69570.0179705000-351691-33.2823
2023-12-31Geode Capital Management, LLC1.51540.000863004810815720.7241
2023-12-31Dafna Capital Management LLC1.44571.7642601032-4500-0.7431
2023-12-31State Street Corporation1.29190.00035371027775616.9275
2023-12-31Morgan Stanley - Brokerage Accounts1.08820.0005452434242506115.5187
2023-12-31StemPoint Capital LP1.01791.3834231744231740
2023-12-31Woodline Partners LP0.83430.04623468633468630
Total 67.884827.529528223214+2797796+9.9%

3.2. Funds holding Kalvista Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.6050.0011083023-70098-6.079
2024-02-29iShares Russell 2000 ETF1.80580.0164750754-123-0.0164
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.06370.0059442221239265.7199
2023-12-31Fidelity Small Cap Index0.74110.01493081206738127.9892
2024-02-01iShares Russell 2000 Value ETF0.69740.03862899483660.1264
2024-01-31Heptagon Driehaus US Micro Cap Eq C$ Acc0.55390.483423027900
2024-02-29iShares Biotechnology ETF0.3960.0296164644-740-0.4474
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.37940.00521577388000.5098
2024-01-31DFA US Small Cap I0.33220.014813812900
2024-01-31Fidelity Extended Market Index0.32980.00613710100
2023-12-31AlphaCentric LifeSci Healthcare I0.32951.610113700020001.4815
2024-01-31DFA US Micro Cap I0.29850.028812410200
2024-02-29Vanguard Russell 2000 ETF0.27130.016111278189008.5675
2023-10-31Goldman Sachs Small Cp Val Insghts Instl0.25140.1071104537-61610-37.0816
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.21460.01298921900
2023-12-31NT R2000 Value Index Fund - NL0.21150.0285879381540121.2319
2023-12-31NT R2000 Index Fund - NL0.210.0148873151538621.3905
2024-01-31Schwab Small Cap Index0.17220.01997159900
2024-02-29iShares Micro-Cap ETF0.16790.1046698086730.9735
2023-12-31Driehaus Micro Cap Growth USD0.1660.37976899816812.4971
Total 11.19722.93834655254+3943+0.1%

3.3. Insider Transactions

Insiders are holding 1.141% of the shares of Kalvista Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-20Edward P FeenerSELL2828814.07
2024-02-20Thomas Andrew CrockettSELL2488814.11
2024-02-20Benjamin L PalleikoSELL2280214.11
2024-02-08Venrock Healthcare Capital ParBUY2974714.7
2024-02-06Venrock Healthcare Capital ParBUY447414.74
2024-01-29Venrock Healthcare Capital ParBUY8060014.22
2024-01-26Venrock Healthcare Capital ParBUY417412.98
2024-01-24Venrock Healthcare Capital ParBUY2068612.44
2024-01-22Venrock Healthcare Capital ParBUY6754612.55
2024-01-18Venrock Healthcare Capital ParBUY3968012.51
2024-01-16Venrock Healthcare Capital ParBUY1959912.73
2024-01-11Edward P FeenerSELL2267913.03
2024-01-10Venrock Healthcare Capital ParBUY4770012.67
2024-01-08Edward P FeenerSELL1722113.01
2024-01-08Venrock Healthcare Capital ParBUY6918412.44
2024-01-03Venrock Healthcare Capital ParBUY1760512.2
2023-12-29Venrock Healthcare Capital ParBUY601312.49
2023-12-27Thomas Andrew CrockettSELL3000012.02
2023-12-27Venrock Healthcare Capital ParBUY4151411.97
2023-09-11Albert ChaSELL1800010.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kalvista Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6130.523-217%-1.231+101%-0.018-97%0.072-946%
Book Value Per Share--2.1002.983-30%2.075+1%2.914-28%1.740+21%
Current Ratio--5.4428.689-37%16.037-66%13.748-60%10.888-50%
Debt To Asset Ratio--0.2230.162+37%0.100+123%0.118+89%0.919-76%
Debt To Equity Ratio--0.2870.197+46%0.111+158%0.136+111%0.203+41%
Dividend Per Share----0%-0%-0%-0%
Eps---0.688-0.642-7%-0.280-59%-0.351-49%-0.227-67%
Free Cash Flow Per Share---0.654-0.575-12%-0.300-54%-0.322-51%-0.207-68%
Free Cash Flow To Equity Per Share---0.647-0.572-12%-0.297-54%-0.054-92%0.029-2310%
Gross Profit Margin--1.0071.002+1%1.000+1%1.000+1%1.000+1%
Intrinsic Value_10Y_max---17.443--------
Intrinsic Value_10Y_min---33.747--------
Intrinsic Value_1Y_max---0.962--------
Intrinsic Value_1Y_min---1.875--------
Intrinsic Value_3Y_max---3.489--------
Intrinsic Value_3Y_min---6.972--------
Intrinsic Value_5Y_max---6.738--------
Intrinsic Value_5Y_min---13.497--------
Market Cap491493695.000-35%665309491.000452364046.750+47%87712854043.500-99%18043008423.300-96%9149420297.428-93%
Net Profit Margin----0%-0%-0.9350%-186.7940%
Operating Margin----0%-0%-1.2350%-162.4630%
Operating Ratio----0%-0%2.298-100%249.791-100%
Pb Ratio5.548-35%7.5113.983+89%523.392-99%109.241-93%57.499-87%
Pe Ratio-4.233+26%-5.730-4.149-28%-1013.369+17586%-213.325+3623%-118.016+1960%
Price Per Share11.650-35%15.77010.723+47%9.528+66%13.768+15%9.916+59%
Price To Free Cash Flow Ratio-4.454+26%-6.029-4.611-24%-1889.662+31245%-391.247+6390%-200.165+3220%
Price To Total Gains Ratio-19.004+26%-25.724-14.380-44%2935.250-101%553.287-105%290.069-109%
Quick Ratio--7.93612.537-37%24.442-68%21.792-64%14.902-47%
Return On Assets---0.255-0.208-18%-0.115-55%-0.118-54%-0.162-36%
Return On Equity---0.328-0.250-24%-0.128-61%-0.135-59%-0.113-65%
Total Gains Per Share---0.6130.523-217%-1.231+101%-0.018-97%0.072-946%
Usd Book Value--88583000.000125847250.000-30%169479750.000-48%139310500.000-36%81602125.000+9%
Usd Book Value Change Per Share---0.6130.523-217%-1.231+101%-0.018-97%0.072-946%
Usd Book Value Per Share--2.1002.983-30%2.075+1%2.914-28%1.740+21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.688-0.642-7%-0.280-59%-0.351-49%-0.227-67%
Usd Free Cash Flow---27590000.000-24265250.000-12%-20156750.000-27%-15075950.000-45%-9474150.000-66%
Usd Free Cash Flow Per Share---0.654-0.575-12%-0.300-54%-0.322-51%-0.207-68%
Usd Free Cash Flow To Equity Per Share---0.647-0.572-12%-0.297-54%-0.054-92%0.029-2310%
Usd Market Cap491493695.000-35%665309491.000452364046.750+47%87712854043.500-99%18043008423.300-96%9149420297.428-93%
Usd Price Per Share11.650-35%15.77010.723+47%9.528+66%13.768+15%9.916+59%
Usd Profit---29028000.000-30507000.000+5%-21439500.000-26%-17495000.000-40%-11063800.000-62%
Usd Revenue----0%-0%3285450.000-100%2193625.000-100%
Usd Total Gains Per Share---0.6130.523-217%-1.231+101%-0.018-97%0.072-946%
 EOD+3 -5MRQTTM+7 -23YOY+9 -215Y+4 -2810Y+8 -24

4.2. Fundamental Score

Let's check the fundamental score of Kalvista Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.233
Price to Book Ratio (EOD)Between0-15.548
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.936
Current Ratio (MRQ)Greater than15.442
Debt to Asset Ratio (MRQ)Less than10.223
Debt to Equity Ratio (MRQ)Less than10.287
Return on Equity (MRQ)Greater than0.15-0.328
Return on Assets (MRQ)Greater than0.05-0.255
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Kalvista Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.580
Ma 20Greater thanMa 5011.572
Ma 50Greater thanMa 10012.901
Ma 100Greater thanMa 20012.185
OpenGreater thanClose11.800
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-01-31. Currency in USD. All numbers in thousands.

Summary
Total Assets113,968
Total Liabilities25,385
Total Stockholder Equity88,583
 As reported
Total Liabilities 25,385
Total Stockholder Equity+ 88,583
Total Assets = 113,968

Assets

Total Assets113,968
Total Current Assets104,103
Long-term Assets9,865
Total Current Assets
Cash And Cash Equivalents 23,056
Short-term Investments 52,530
Net Receivables 23,682
Other Current Assets 4,835
Total Current Assets  (as reported)104,103
Total Current Assets  (calculated)104,103
+/-0
Long-term Assets
Property Plant Equipment 9,468
Long-term Assets Other 397
Long-term Assets  (as reported)9,865
Long-term Assets  (calculated)9,865
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,128
Long-term Liabilities6,257
Total Stockholder Equity88,583
Total Current Liabilities
Short-term Debt 1,187
Accounts payable 3,101
Other Current Liabilities 14,840
Total Current Liabilities  (as reported)19,128
Total Current Liabilities  (calculated)19,128
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,257
Long-term Liabilities  (as reported)6,257
Long-term Liabilities  (calculated)6,257
+/-0
Total Stockholder Equity
Common Stock34
Retained Earnings -425,077
Accumulated Other Comprehensive Income -3,294
Other Stockholders Equity 516,920
Total Stockholder Equity (as reported)88,583
Total Stockholder Equity (calculated)88,583
+/-0
Other
Capital Stock34
Cash and Short Term Investments 75,586
Common Stock Shares Outstanding 34,723
Liabilities and Stockholders Equity 113,968
Net Debt -15,612
Net Invested Capital 88,583
Net Working Capital 84,975
Property Plant and Equipment Gross 9,468
Short Long Term Debt Total 7,444



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-312016-10-312016-07-312016-04-302016-01-312015-10-312015-07-312015-04-302015-01-312014-10-312014-07-312014-04-302014-01-312013-10-31
> Total Assets 
10,105
0
0
10,858
6,644
7,712
7,712
67,598
62,079
56,791
49,675
38,007
35,863
38,050
34,345
30,784
34,741
66,657
61,389
57,618
132,559
126,525
118,132
119,884
112,064
102,935
92,529
83,902
75,448
66,206
272,013
259,133
243,810
225,052
203,880
182,319
162,838
203,468
183,202
160,332
138,743
113,968
113,968138,743160,332183,202203,468162,838182,319203,880225,052243,810259,133272,01366,20675,44883,90292,529102,935112,064119,884118,132126,525132,55957,61861,38966,65734,74130,78434,34538,05035,86338,00749,67556,79162,07967,5987,7127,7126,64410,8580010,105
   > Total Current Assets 
9,910
0
0
9,488
4,587
4,308
4,308
66,995
61,449
54,945
49,465
37,957
35,813
37,953
34,248
30,192
34,139
65,710
59,380
55,185
130,070
124,063
115,546
115,719
107,892
99,005
88,696
80,225
72,076
62,504
264,264
249,782
234,478
214,464
193,647
170,407
151,216
192,133
172,326
149,842
128,606
104,103
104,103128,606149,842172,326192,133151,216170,407193,647214,464234,478249,782264,26462,50472,07680,22588,69699,005107,892115,719115,546124,063130,07055,18559,38065,71034,13930,19234,24837,95335,81337,95749,46554,94561,44966,9954,3084,3084,5879,488009,910
       Cash And Cash Equivalents 
9,781
0
0
9,325
3,897
3,181
3,181
65,381
59,878
53,723
48,455
36,819
35,208
33,498
30,950
26,456
28,128
58,678
51,055
48,070
121,116
56,345
32,006
30,107
21,719
18,615
15,789
18,014
16,174
17,727
50,592
48,343
46,491
45,577
30,732
37,863
38,585
85,049
56,238
49,409
57,666
23,056
23,05657,66649,40956,23885,04938,58537,86330,73245,57746,49148,34350,59217,72716,17418,01415,78918,61521,71930,10732,00656,345121,11648,07051,05558,67828,12826,45630,95033,49835,20836,81948,45553,72359,87865,3813,1813,1813,8979,325009,781
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54,802
68,805
70,259
71,742
61,955
51,925
46,317
39,700
32,584
198,337
182,288
163,322
149,212
135,470
104,212
83,688
86,636
93,137
73,848
45,506
52,530
52,53045,50673,84893,13786,63683,688104,212135,470149,212163,322182,288198,33732,58439,70046,31751,92561,95571,74270,25968,80554,802000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
2,239
2,239
0
0
3,238
2,547
2,895
4,611
5,029
6,834
5,604
7,032
8,970
11,315
12,625
11,814
14,803
16,527
12,638
14,685
7,589
10,418
13,613
17,399
11,287
14,098
17,248
21,930
11,892
16,568
20,570
21,299
23,682
23,68221,29920,57016,56811,89221,93017,24814,09811,28717,39913,61310,4187,58914,68512,63816,52714,80311,81412,62511,3158,9707,0325,6046,8345,0294,6112,8952,5473,238002,2392,239000000000
       Other Current Assets 
129
0
0
163
690
1,127
1,614
1,571
1,571
1,222
1,138
605
605
1,217
751
841
1,400
2,003
1,491
1,511
1,922
3,946
3,420
2,728
2,617
3,632
4,455
3,256
1,517
4,604
4,917
19,151
7,266
8,388
10,638
9,043
7,013
8,556
6,383
26,585
25,434
4,835
4,83525,43426,5856,3838,5567,0139,04310,6388,3887,26619,1514,9174,6041,5173,2564,4553,6322,6172,7283,4203,9461,9221,5111,4912,0031,4008417511,2176056051,1381,2221,5711,5711,6141,12769016300129
   > Long-term Assets 
195
0
0
1,370
2,057
2,846
3,404
603
630
1,846
210
50
50
97
97
592
602
947
2,009
2,433
2,489
2,462
2,586
4,165
4,172
3,930
3,833
3,677
3,372
3,702
7,749
9,351
9,332
10,588
10,233
11,912
11,622
11,335
10,876
10,490
10,137
9,865
9,86510,13710,49010,87611,33511,62211,91210,23310,5889,3329,3517,7493,7023,3723,6773,8333,9304,1724,1652,5862,4622,4892,4332,009947602592979750502101,8466306033,4042,8462,0571,37000195
       Property Plant Equipment 
75
0
0
121
180
329
329
374
362
805
160
0
0
97
97
592
602
774
1,836
2,260
2,316
2,289
2,413
3,992
3,999
3,757
3,655
3,499
3,194
3,521
7,549
9,151
9,139
10,395
10,040
11,694
11,425
11,138
10,770
10,384
9,800
9,468
9,4689,80010,38410,77011,13811,42511,69410,04010,3959,1399,1517,5493,5213,1943,4993,6553,7573,9993,9922,4132,2892,3162,2601,8367746025929797001608053623743293291801210075
       Long-term Assets Other 
120
0
0
1,249
1,877
229
3,075
229
268
1,041
50
50
50
0
0
0
0
173
173
173
173
173
173
173
173
173
178
178
178
181
200
200
193
193
193
218
197
197
106
106
337
397
39733710610619719721819319319320020018117817817817317317317317317317317317300005050501,0412682293,0752291,8771,24900120
> Total Liabilities 
43,813
0
0
50,499
50,825
56,681
56,681
8,274
7,458
7,481
6,604
1,971
1,926
3,201
3,018
4,050
3,662
38,089
34,136
31,368
25,608
22,492
21,394
18,017
14,277
13,188
8,777
9,467
10,468
7,641
14,820
14,703
16,338
17,116
18,787
17,747
19,025
19,027
22,177
20,997
24,297
25,385
25,38524,29720,99722,17719,02719,02517,74718,78717,11616,33814,70314,8207,64110,4689,4678,77713,18814,27718,01721,39422,49225,60831,36834,13638,0893,6624,0503,0183,2011,9261,9716,6047,4817,4588,27456,68156,68150,82550,4990043,813
   > Total Current Liabilities 
3,950
0
0
7,563
7,093
11,005
11,005
4,167
3,793
4,271
3,854
1,929
1,891
3,201
3,018
3,837
3,513
24,083
23,216
22,903
20,938
18,826
18,052
13,967
10,470
9,762
7,720
8,457
9,536
6,518
9,774
8,229
10,114
9,649
11,576
9,733
11,320
11,606
15,032
14,132
17,751
19,128
19,12817,75114,13215,03211,60611,3209,73311,5769,64910,1148,2299,7746,5189,5368,4577,7209,76210,47013,96718,05218,82620,93822,90323,21624,0833,5133,8373,0183,2011,8911,9293,8544,2713,7934,16711,00511,0057,0937,563003,950
       Short-term Debt 
3,063
0
0
4,390
4,435
6,599
6,599
480
965
1,455
1,950
282
0
0
0
202
220
222
221
214
157
109
54
580
602
592
588
513
422
592
863
905
930
1,014
977
997
1,026
1,057
1,087
1,122
1,148
1,187
1,1871,1481,1221,0871,0571,0269979771,014930905863592422513588592602580541091572142212222202020002821,9501,4559654806,5996,5994,4354,390003,063
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1,950
1,950
0
0
0
0
415
369
339
279
214
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000021427933936941500001,9501,950000000000
       Accounts payable 
462
0
0
1,237
1,024
4,377
2,545
1,992
1,527
1,460
793
187
431
755
1,153
1,943
1,040
1,575
1,433
2,345
3,018
2,998
2,860
3,103
2,238
2,951
1,677
1,774
2,173
641
1,981
1,448
3,159
2,185
3,638
2,908
3,384
1,698
4,817
5,060
4,896
3,101
3,1014,8965,0604,8171,6983,3842,9083,6382,1853,1591,4481,9816412,1731,7741,6772,9512,2383,1032,8602,9983,0182,3451,4331,5751,0401,9431,1537554311877931,4601,5271,9922,5454,3771,0241,23700462
       Other Current Liabilities 
396
0
0
1,907
1,605
29
1,832
1,666
1,272
1,327
1,082
1,431
1,431
2,446
1,865
1,692
2,253
2,290
3,087
3,137
2,994
3,408
5,593
4,261
5,029
4,876
5,455
6,170
6,941
5,285
6,930
5,876
6,025
6,450
6,961
5,828
6,910
8,851
9,128
7,950
11,707
14,840
14,84011,7077,9509,1288,8516,9105,8286,9616,4506,0255,8766,9305,2856,9416,1705,4554,8765,0294,2615,5933,4082,9943,1373,0872,2902,2531,6921,8652,4461,4311,4311,0821,3271,2721,6661,832291,6051,90700396
   > Long-term Liabilities 
39,863
0
0
42,936
43,732
6,120
45,676
4,107
3,665
3,210
2,750
42
35
755
1,153
213
149
14,006
10,920
8,465
4,670
3,666
3,342
4,050
3,807
3,426
1,057
1,010
932
1,123
5,046
6,474
6,224
7,467
7,211
8,014
7,705
7,421
7,145
6,865
6,546
6,257
6,2576,5466,8657,1457,4217,7058,0147,2117,4676,2246,4745,0461,1239321,0101,0573,4263,8074,0503,3423,6664,6708,46510,92014,0061492131,15375535422,7503,2103,6654,10745,6766,12043,73242,9360039,863
       Long term Debt Total 
0
0
0
0
0
3,404
4,036
3,601
3,154
2,701
0
0
0
0
0
213
149
117
58
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000058117149213000002,7013,1543,6014,0363,40400000
       Warrants
0
0
0
0
0
39,556
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000039,55600000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,889
10,862
8,465
4,670
3,666
3,342
2,873
2,754
2,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,5002,7542,8733,3423,6664,6708,46510,86213,88900000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
2,367
71
64
56
49
42
35
0
0
0
0
0
13,889
10,862
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000010,86213,889000003542495664712,36700000
> Total Stockholder Equity
-33,708
0
0
-39,641
-44,181
-48,969
-48,969
59,324
54,621
49,310
43,071
36,036
33,937
34,849
31,327
26,734
31,079
28,568
27,253
26,250
106,951
104,033
96,738
101,867
97,787
89,747
83,752
74,435
64,980
58,565
257,193
244,430
227,472
207,936
185,093
164,572
143,813
184,441
161,025
139,335
114,446
88,583
88,583114,446139,335161,025184,441143,813164,572185,093207,936227,472244,430257,19358,56564,98074,43583,75289,74797,787101,86796,738104,033106,95126,25027,25328,56831,07926,73431,32734,84933,93736,03643,07149,31054,62159,324-48,969-48,969-44,181-39,64100-33,708
   Common Stock
2
0
0
3
1
1
1
27
27
27
27
27
27
10
10
10
11
11
11
11
17
17
17
18
18
18
18
18
18
18
24
24
24
24
25
25
25
34
34
34
34
34
34343434342525252424242418181818181818171717111111111010102727272727271113002
   Retained Earnings -425,077-396,049-368,399-343,082-316,777-295,474-273,217-250,175-226,062-203,595-183,945-167,836-152,880-142,832-132,406-121,592-115,008-105,717-99,814-92,476-83,950-79,994-76,690-71,660-71,003-65,769-60,784-55,855-51,653-88,963-86,577-79,228-72,621-66,962-61,971-52,959-52,959-47,775-43,06100-34,416
   Accumulated Other Comprehensive Income -3,294-3,465-2,891-3,060-3,541-5,326-4,150-3,861-2,339-1,720-1,489-1,432-1,267-1,956-1,619-1,882-1,382-1,464-1,987-1,926-2,101-2,236-2,429-1,109-136-2,571-2,528-2,643-2,90700-215-628-62,079-593-560-526-495-47800-441
   Capital Surplus 
0
0
0
0
0
3,989
121,268
121,556
121,904
122,272
122,586
122,873
0
89,399
89,815
90,036
99,408
99,696
100,011
105,358
189,164
190,067
191,123
203,650
204,950
206,119
207,208
208,442
209,750
212,694
426,437
426,437
432,763
436,313
439,104
441,914
444,588
504,725
507,133
0
0
0
000507,133504,725444,588441,914439,104436,313432,763426,437426,437212,694209,750208,442207,208206,119204,950203,650191,123190,067189,164105,358100,01199,69699,40890,03689,81589,3990122,873122,586122,272121,904121,556121,2683,98900000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
1,147
0
0
3,895
4,088
0
4,200
54,263
121,556
122,532
122,272
122,586
122,873
89,399
89,815
90,036
99,408
99,696
100,011
105,358
189,164
190,067
191,123
203,650
204,950
206,119
207,208
208,442
209,750
212,694
426,437
428,351
432,763
436,313
439,104
441,914
444,588
504,725
507,133
510,591
513,926
516,920
516,920513,926510,591507,133504,725444,588441,914439,104436,313432,763428,351426,437212,694209,750208,442207,208206,119204,950203,650191,123190,067189,164105,358100,01199,69699,40890,03689,81589,399122,873122,586122,272122,532121,55654,2634,20004,0883,895001,147



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-04-30)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-802
Gross Profit-802-802
 
Operating Income (+$)
Gross Profit-802
Operating Expense-110,871
Operating Income-110,871-111,673
 
Operating Expense (+$)
Research Development80,276
Selling General Administrative30,595
Selling And Marketing Expenses0
Operating Expense110,871110,871
 
Net Interest Income (+$)
Interest Income2,232
Interest Expense-17,964
Other Finance Cost-17,964
Net Interest Income2,232
 
Pretax Income (+$)
Operating Income-110,871
Net Interest Income2,232
Other Non-Operating Income Expenses17,964
Income Before Tax (EBT)-92,907-128,835
EBIT - interestExpense = -128,835
-92,907
-56,889
Interest Expense17,964
Earnings Before Interest and Taxes (EBIT)-110,871-74,943
Earnings Before Interest and Taxes (EBITDA)-110,243
 
After tax Income (+$)
Income Before Tax-92,907
Tax Provision-0
Net Income From Continuing Ops-92,907-92,907
Net Income-74,853
Net Income Applicable To Common Shares-92,907
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses110,871
Total Other Income/Expenses Net17,964-20,196
 

Technical Analysis of Kalvista
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kalvista. The general trend of Kalvista is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kalvista's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kalvista Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 12.70 < 14.80 < 16.88.

The bearish price targets are: 10.70 > 10.32 > 9.89.

Tweet this
Kalvista Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kalvista Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kalvista Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kalvista Pharmaceuticals Inc. The current macd is -0.25066224.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kalvista price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kalvista. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kalvista price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Kalvista Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartKalvista Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kalvista Pharmaceuticals Inc. The current adx is 13.77.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kalvista shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Kalvista Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kalvista Pharmaceuticals Inc. The current sar is 12.24.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kalvista Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kalvista Pharmaceuticals Inc. The current rsi is 45.58. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Kalvista Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartKalvista Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kalvista Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kalvista price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kalvista Pharmaceuticals Inc Daily Stochastic Oscillator ChartKalvista Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kalvista Pharmaceuticals Inc. The current cci is 35.75.

Kalvista Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartKalvista Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kalvista Pharmaceuticals Inc. The current cmo is -5.91343674.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kalvista Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartKalvista Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kalvista Pharmaceuticals Inc. The current willr is -48.95168642.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kalvista is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kalvista Pharmaceuticals Inc Daily Williams %R ChartKalvista Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kalvista Pharmaceuticals Inc.

Kalvista Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kalvista Pharmaceuticals Inc. The current atr is 0.63793479.

Kalvista Pharmaceuticals Inc Daily Average True Range (ATR) ChartKalvista Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kalvista Pharmaceuticals Inc. The current obv is -213,771.

Kalvista Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartKalvista Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kalvista Pharmaceuticals Inc. The current mfi is 55.70.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Kalvista Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartKalvista Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kalvista Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Kalvista Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kalvista Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.580
Ma 20Greater thanMa 5011.572
Ma 50Greater thanMa 10012.901
Ma 100Greater thanMa 20012.185
OpenGreater thanClose11.800
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kalvista with someone you think should read this too:
  • Are you bullish or bearish on Kalvista? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kalvista? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kalvista Pharmaceuticals Inc

I send you an email if I find something interesting about Kalvista Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kalvista Pharmaceuticals Inc.

Receive notifications about Kalvista Pharmaceuticals Inc in your mailbox!